Open questions in current models of antidepressant action

British Journal of Pharmacology

Volumn 159, Issue 6, 2010, Pages 1187-1200

  Tanti, A ^a   Belzung, C ^a  

^a UNIVERSITÉ DE TOURS   (France)

Author keywords

Amygdala; Antidepressant; Cingulate cortex; Depression; Glutamate; Hippocampus; Hypothalamic pituitary adrenal axis; Neuroplasticity; Prefrontal cortex; Serotonin

Indexed keywords

ANTIDEPRESSANT AGENT; BRAIN DERIVED NEUROTROPHIC FACTOR; CORTICOTROPIN RELEASING FACTOR ANTAGONIST; FLUOXETINE; FLUVOXAMINE; GLUCOCORTICOID RECEPTOR; NEUROTRANSMITTER; NORADRENALIN; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; TIANEPTINE; UNCLASSIFIED DRUG; VASOPRESSIN V1B RECEPTOR ANTAGONIST; VENLAFAXINE;

ANHEDONIA; ANXIETY DISORDER; CINGULATE GYRUS; CLINICAL TRIAL; COGNITIVE DEFECT; COGNITIVE THERAPY; COMORBIDITY; COPING BEHAVIOR; DEPRESSION; DRUG MECHANISM; ELECTROCONVULSIVE THERAPY; EXPERIMENTAL MODEL; GENERALIZED ANXIETY DISORDER; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; LONG TERM DEPRESSION; LONG TERM POTENTIATION; MAJOR DEPRESSION; NERVE CELL PLASTICITY; NEUROTRANSMISSION; NONHUMAN; PATHOPHYSIOLOGY; PHENOTYPE; PREFRONTAL CORTEX; PRIORITY JOURNAL; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SLEEP WAKING CYCLE;

ANIMALS; ANTIDEPRESSIVE AGENTS; BRAIN; DEPRESSIVE DISORDER, MAJOR; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; ENDPOINT DETERMINATION; HUMANS; MODELS, BIOLOGICAL; NEURONAL PLASTICITY; SYNAPTIC TRANSMISSION;

EID: 77949387830     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2009.00585.x     Document Type: Review

References (151)

1. Airan RD, Meltzer LA, Roy M, Gong Y, Chen H, Deisseroth K (2007). High-speed imaging reveals neurophysiological links to behavior in an animal model of depression. Science 317: 819-823.
2. Alexander SP, Mathie A, Peters JA (2008). Guide to Receptors and Channels (GRAC), 3rd edition. Br J Pharmacol 153 (Suppl. 2): S1-S209.
3. Alonso R, Griebel G, Pavone G, Stemmelin J, Le FG, Soubrie P (2004). Blockade of CRF(1) or V(1b) receptors reverses stress-induced suppression of neurogenesis in a mouse model of depression. Mol Psychiatry 9: 278-286.
4. Amsterdam JD (1998). Selective serotonin reuptake inhibitor efficacy in severe and melancholic depression. J Psychopharmacol 12: S99-S111.
5. Anand A, Li Y,Wang Y,Wu J, Gao S, Bukhari L et al. (2005). Activity and connectivity of brain mood regulating circuit in depression: a functional magnetic resonance study. Biol Psychiatry 57: 1079-1088.
6. Asberg M, Thoren P, Traskman L, Bertilsson L, Ringberger V (1976). 'Serotonin depression' - a biochemical subgroup within the affective disorders? Science 191: 478-480.
7. Banasr M, Duman RS (2008). Glial loss in the prefrontal cortex is sufficient to induce depressive-like behaviors. Biol Psychiatry 64: 863-870.
8. Bechtholt AJ, Valentino RJ, Lucki I (2008). Overlapping and distinct brain regions associated with the anxiolytic effects of chlordiazepoxide and chronic fluoxetine. Neuropsychopharmacology 33: 2117-2130.
9. Belzung C, Philippot P (2007). Anxiety from a phylogenetic perspective: is there a qualitative difference between human and animal anxiety? Neural Plast 2007: 59676.
10. Berton O, McClung CA, Dileone RJ, Krishnan V, Renthal W, Russo SJ et al. (2006). Essential role of BDNF in the mesolimbic dopamine pathway in social defeat stress. Science 311: 864-868.
11. Bessa JM, Ferreira D, Melo I, Marques F, Cerqueira JJ, Palha JA et al. (2009). The mood-improving actions of antidepressants do not depend on neurogenesis but are associated with neuronal remodeling. Mol Psychiatry 14: 764-773.
12. Binder EB, Salyakina D, Lichtner P,Wochnik GM, Ising M, Putz B et al. (2004). Polymorphisms in FKBP5 are associated with increased recurrence of depressive episodes and rapid response to antidepressant treatment. Nat Genet 36: 1319-1325.
13. Binneman B, Feltner D, Kolluri S, Shi Y, Qiu R, Stiger T (2008). A 6-week randomized, placebo-controlled trial of CP-316,311 (a selective CRH1 antagonist) in the treatment of major depression. Am J Psychiatry 165: 617-620.
14. Blier P, de Montigny C (1998). Possible serotonergic mechanisms underlying the antidepressant and anti-obsessive-compulsive disorder responses. Biol Psychiatry 44: 313-323.
15. Bonanno G, Giambelli R, Raiteri L, Tiraboschi E, Zappettini S, Musazzi L et al. (2005). Chronic antidepressants reduce depolarizationevoked glutamate release and protein interactions favoring formation of SNARE complex in hippocampus. J Neurosci 25: 3270-3279.
16. Boyle MP, Brewer JA, Funatsu M, Wozniak DF, Tsien JZ, Izumi Y et al. (2005). Acquired deficit of forebrain glucocorticoid receptor produces depression-like changes in adrenal axis regulation and behavior. Proc Natl Acad Sci USA 102: 473-478.
17. Brouwer JP, Appelhof BC, van Rossum EF, Koper JW, Fliers E, Huyser J et al. (2006). Prediction of treatment response by HPA-axis and glucocorticoid receptor polymorphisms in major depression. Psychoneuroendocrinology 31: 1154-1163.
18. Carroll BJ, Feinberg M, Greden JF, Tarika J, Albala AA, Haskett RF et al. (1981). A specific laboratory test for the diagnosis of melancholia. Standardization, validation, and clinical utility. Arch Gen Psychiatry 38: 15-22.
19. Cerqueira JJ, Mailliet F, Almeida OF, Jay TM, Sousa N (2007). The prefrontal cortex as a key target of the maladaptive response to stress. J Neurosci 27: 2781-2787.
20. Chapman LJ, Chapman JP, Raulin ML (1976). Scales for physical and social anhedonia. J Abnorm Psychol 85: 374-382.
21. Chaput Y, de MC, Blier P (1991). Presynaptic and postsynaptic modifications of the serotonin system by long-term administration of antidepressant treatments. An in vivo electrophysiologic study in the rat. Neuropsychopharmacology 5: 219-229.
22. Chen CH, Ridler K, Suckling J, Williams S, Fu CH, Merlo-Pich E et al. (2007). Brain imaging correlates of depressive symptom severity and predictors of symptom improvement after antidepressant treatment. Biol Psychiatry 62: 407-414.
23. Coppen A, Eccleston EG, Peet M (1973). Total and free tryptophan concentration in the plasma of depressive patients. Lancet 2: 60-63.
24. Cowen PJ, Parry-Billings M, Newsholme EA (1989). Decreased plasma tryptophan levels in major depression. J Affect Disord 16: 27-31.
25. Cryan JF, Dalvi A, Jin SH, Hirsch BR, Lucki I, Thomas SA (2001). Use of dopamine-beta-hydroxylase-deficient mice to determine the role of norepinephrine in the mechanism of action of antidepressant drugs. J Pharmacol Exp Ther 298: 651-657.
26. Cryan JF, O'Leary OF, Jin SH, Friedland JC, Ouyang M, Hirsch BR et al. (2004). Norepinephrine-deficient mice lack responses to antidepressant drugs, including selective serotonin reuptake inhibitors. Proc Natl Acad Sci USA 101: 8186-8191.
27. Czeh B, Michaelis T,Watanabe T, Frahm J, de BG, van KM et al. (2001). Stress-induced changes in cerebral metabolites, hippocampal volume, and cell proliferation are prevented by antidepressant treatment with tianeptine. Proc Natl Acad Sci USA 98: 12796-12801.
28. David DJ, Klemenhagen KC, Holick KA, Saxe MD, Mendez I, Santarelli L et al. (2007). Efficacy of the MCHR1 antagonist N-[3-(1-{[4-(3,4- difluorophenoxy)phenyl]methyl} (4-piperidyl))-4-methylphenyl]-2- methylpropanamide (SNAP 94847) in mouse models of anxiety and depression following acute and chronic administration is independent of hippocampal neurogenesis. J Pharmacol Exp Ther 321: 237-248.
29. David DJ, Samuels BA, Rainer Q, Wang JW, Marsteller D, Mendez I et al. (2009). Neurogenesis-dependent and -independent effects of fluoxetine in an animal model of anxiety/depression. Neuron 62: 479-493.
30. Davidson RJ, Irwin W, Anderle MJ, Kalin NH (2003). The neural substrates of affective processing in depressed patients treated with venlafaxine. Am J Psychiatry 160: 64-75.
31. Davis M, Whalen PJ (2001). The amygdala: vigilance and emotion. Mol Psychiatry 6: 13-34.
32. Delgado PL, Miller HL, Salomon RM, Licinio J, Krystal JH, Moreno FA et al. (1999). Tryptophan-depletion challenge in depressed patients treated with desipramine or fluoxetine: implications for the role of serotonin in the mechanism of antidepressant action. Biol Psychiatry 46: 212-220.
33. Derijk RH, de Kloet ER (2008). Corticosteroid receptor polymorphisms: determinants of vulnerability and resilience. Eur J Pharmacol 583: 303-311.
34. Drevets WC (2000). Neuroimaging studies of mood disorders. Biol Psychiatry 48: 813-829.
35. Drevets WC, Frank E, Price JC, Kupfer DJ, Holt D, Greer PJ et al. (1999). PET imaging of serotonin 1A receptor binding in depression. Biol Psychiatry 46: 1375-1387.
36. Drevets WC, Thase ME, Moses-Kolko EL, Price J, Frank E, Kupfer DJ et al. (2007). Serotonin-1A receptor imaging in recurrent depression: replication and literature review. Nucl Med Biol 34: 865-877.
37. Drevets WC, Price JL, Furey ML (2008). Brain structural and functional abnormalities in mood disorders: implications for neurocircuitry models of depression. Brain Struct Funct 213: 93-118.
38. Ducottet C, Griebel G, Belzung C (2003). Effects of the selective nonpeptide corticotropin-releasing factor receptor 1 antagonist antalarmin in the chronic mild stress model of depression in mice. Prog Neuropsychopharmacol Biol Psychiatry 27: 625-631.
39. Duman RS, Monteggia LM (2006). A neurotrophic model for stress-related mood disorders. Biol Psychiatry 59: 1116-1127.
40. Epstein J, Pan H, Kocsis JH, Yang Y, Butler T, Chusid J et al. (2006). Lack of ventral striatal response to positive stimuli in depressed versus normal subjects. Am J Psychiatry 163: 1784-1790.
41. Fitzgerald PB, Laird AR, Maller J, Daskalakis ZJ (2008). A meta-analytic study of changes in brain activation in depression. Hum Brain Mapp 29: 683-695.
42. Frodl T, Meisenzahl E, Zetzsche T, Bottlender R, Born C, Groll C et al. (2002). Enlargement of the amygdala in patients with a first episode of major depression. Biol Psychiatry 51: 708-714.
43. Frodl T, Meisenzahl EM, Zetzsche T, Born C, Jager M, Groll C et al. (2003). Larger amygdala volumes in first depressive episode as compared to recurrent major depression and healthy control subjects. Biol Psychiatry 53: 338-344.
44. Fu CH, Williams SC, Brammer MJ, Suckling J, Kim J, Cleare AJ et al. (2007). Neural responses to happy facial expressions in major depression following antidepressant treatment. Am J Psychiatry 164: 599-607.
45. Fu CH, Williams SC, Cleare AJ, Scott J, Mitterschiffthaler MT, Walsh ND et al. (2008). Neural responses to sad facial expressions in major depression following cognitive behavioral therapy. Biol Psychiatry 64: 505-512.
46. Gatt JM, Nemeroff CB, Dobson-Stone C, Paul RH, Bryant RA, Schofield PR et al. (2009). Interactions between BDNF Val66Met polymorphism and early life stress predict brain and arousal pathways to syndromal depression and anxiety. Mol Psychiatry 14: 681-695.
47. Gervasoni N, Bertschy G, Osiek C, Perret G, Denis R, Golaz J et al. (2004). Cortisol responses to combined dexamethasone/CRH test in outpatients with a major depressive episode. J Psychiatr Res 38: 553-557.
48. Gold PW, Chrousos G, Kellner C, Post R, Roy A, Augerinos P et al. (1984). Psychiatric implications of basic and clinical studies with corticotropin-releasing factor. Am J Psychiatry 141: 619-627.
49. Goldapple K, Segal Z, Garson C, Lau M, Bieling P, Kennedy S et al. (2004). Modulation of cortical-limbic pathways in major depression: treatment-specific effects of cognitive behavior therapy. Arch Gen Psychiatry 61: 34-41.
50. Golimbet VE, Lebedeva IS, Korovaitseva GI, Lezheiko TV, Yumatova PE (2008). Association of 5-HTTLPR serotonin transporter gene polymorphism and Val66Met brain-derived neurotrophic factor gene polymorphism with auditory N100 evoked potential amplitude in patients with endogenous psychoses. Bull Exp Biol Med 146: 605-608.
51. Greenberg PE, Kessler RC, Birnbaum HG, Leong SA, Lowe SW, Berglund PA et al. (2003). The economic burden of depression in the United States: how did it change between 1990 and 2000? J Clin Psychiatry 64: 1465-1475.
52. Griebel G, Simiand J, Serradeil-Le GC, Wagnon J, Pascal M, Scatton B et al. (2002). Anxiolytic- and antidepressant-like effects of the nonpeptide vasopressin V1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders. Proc Natl Acad Sci USA 99: 6370-6375.
53. Hashimoto K (2009). Emerging role of glutamate in the pathophysiology of major depressive disorder. Brain Res Rev 61: 105-123.
54. Hettema JM (2008). What is the genetic relationship between anxiety and depression?. Am J Med Genet C Semin Med Genet 148C: 140-146.
55. Holderbach R, Clark K, Moreau JL, Bischofberger J, Normann C (2007). Enhanced long-term synaptic depression in an animal model of depression. Biol Psychiatry 62: 92-100.
56. Holsboer F (2000). The corticosteroid receptor hypothesis of depression. Neuropsychopharmacology 23: 477-501.
57. Holsboer F, Barden N (1996). Antidepressants and hypothalamic-pituitary- adrenocortical regulation. Endocr Rev 17: 187-205.
58. Holsboer F, Ising M (2008). Central CRH system in depression and anxiety - evidence from clinical studies with CRH1 receptor antagonists. Eur J Pharmacol 583: 350-357.
59. Holsboer F, Von BU, Gerken A, Stalla GK, Muller OA (1984). Blunted corticotropin and normal cortisol response to human corticotropin-releasing factor in depression. N Engl J Med 311: 1127.
60. Huang R, Huang J, Cathcart H, Smith S, Poduslo SE (2007). Genetic variants in brain-derived neurotrophic factor associated with Alzheimer's disease. J Med Genet 44: e66.
61. Ibarguen-Vargas Y, Surget A, Touma C, Palme R, Belzung C (2008). Multifaceted strain-specific effects in a mouse model of depression and of antidepressant reversal. Psychoneuroendocrinology 33: 1357-1368.
62. Ising M, Horstmann S, Kloiber S, Lucae S, Binder EB, Kern N et al. (2007). Combined dexamethasone/corticotropin releasing hormone test predicts treatment response in major depression - a potential biomarker? Biol Psychiatry 62: 47-54.
63. Jakovljevic M, Muck-Seler D, Pivac N, Ljubicic D, Bujas M, Dodig G (1997). Seasonal influence on platelet 5-HT levels in patients with recurrent major depression and schizophrenia. Biol Psychiatry 41: 1028-1034.
64. Jiang W, Zhang Y, Xiao L, Van CJ, Ji SP, Bai G et al. (2005). Cannabinoids promote embryonic and adult hippocampus neurogenesis and produce anxiolytic- and antidepressant-like effects. J Clin Invest 115: 3104-3116.
65. Jiang X, Zhou J, Mash DC, Marini AM, Lipsky RH (2009). Human BDNF isoforms are differentially expressed in cocaine addicts and are sorted to the regulated secretory pathway independent of the Met66 substitution. Neuromolecular Med 11: 1-12.
66. Kato M, Serretti A (2008). Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder. Mol Psychiatry (in press).
67. Kendler KS (1996). Major depression and generalised anxiety disorder. Same genes, (partly)different environments - revisited. Br J Psychiatry Suppl 30: 68-75.
68. Kendler KS, Neale MC, Kessler RC, Heath AC, Eaves LJ (1992). Major depression and generalized anxiety disorder. Same genes, (partly) different environments? Arch Gen Psychiatry 49: 716-722.
69. Kendler KS, Gardner CO, Gatz M, Pedersen NL (2007). The sources of co-morbidity between major depression and generalized anxiety disorder in a Swedish national twin sample. Psychol Med 37: 453-462.
70. Kessler RC, Berglund P, Demler O, Jin R, Koretz D, Merikangas KR et al. (2003). The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 289: 3095-3105.
71. Koenigs M, Grafman J (2009). The functional neuroanatomy of depression: distinct roles for ventromedial and dorsolateral prefrontal cortex. Behav Brain Res 201: 239-243.
72. Koponen E, Rantamaki T, Voikar V, Saarelainen T, MacDonald E, Castren E (2005). Enhanced BDNF signaling is associated with an antidepressant-like behavioral response and changes in brain monoamines. Cell Mol Neurobiol 25: 973-980.
73. Krabbe KS, Nielsen AR, Krogh-Madsen R, Plomgaard P, Rasmussen P, Erikstrup C et al. (2007). Brain-derived neurotrophic factor (BDNF) and type 2 diabetes. Diabetologia 50: 431-438.
74. Li X, Need AB, Baez M, Witkin JM (2006). Metabotropic glutamate 5 receptor antagonism is associated with antidepressant-like effects in mice. J Pharmacol Exp Ther 319: 254-259.
75. Li Y, Luikart BW, Birnbaum S, Chen J, Kwon CH, Kernie SG et al. (2008). TrkB regulates hippocampal neurogenesis and governs sensitivity to antidepressive treatment. Neuron 59: 399-412.
76. Louis C, Cohen C, Depoortere R, Griebel G (2006). Antidepressant-like effects of the corticotropin-releasing factor 1 receptor antagonist, SSR125543, and the vasopressin 1b receptor antagonist, SSR149415, in a DRL-72 s schedule in the rat. Neuropsychopharmacology 31: 2180-2187.
77. McEwen BS, Magarinos AM, Reagan LP (2002). Structural plasticity and tianeptine: cellular and molecular targets. Eur Psychiatry 17 (Suppl. 3): 318-330.
78. MacQueen GM, Campbell S, McEwen BS, Macdonald K, Amano S, Joffe RT et al. (2003). Course of illness, hippocampal function, and hippocampal volume in major depression. Proc Natl Acad Sci USA 100: 1387-1392.
79. Malberg JE, Eisch AJ, Nestler EJ, Duman RS (2000). Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus. J Neurosci 20: 9104-9110.
80. Manev R, Uz T, Manev H (2001). Fluoxetine increases the content of neurotrophic protein S100beta in the rat hippocampus. Eur J Pharmacol 420: R1-R2.
81. Maroun M (2006). Stress reverses plasticity in the pathway projecting from the ventromedial prefrontal cortex to the basolateral amygdala. Eur J Neurosci 24: 2917-2922.
82. Maroun M, Richter-Levin G (2003). Exposure to acute stress blocks the induction of long-term potentiation of the amygdala-prefrontal cortex pathway in vivo. J Neurosci 23: 4406-4409.
83. Mayberg HS, Brannan SK, Mahurin RK, Jerabek PA, Brickman JS, Tekell JL et al. (1997). Cingulate function in depression: a potential predictor of treatment response. Neuroreport 8: 1057-1061.
84. Meltzer CC, Price JC, Mathis CA, Butters MA, Ziolko SK, Moses-Kolko E et al. (2004). Serotonin 1A receptor binding and treatment response in late-life depression. Neuropsychopharmacology 29: 2258-2265.
85. Miller BH, Schultz LE, Gulati A, Cameron MD, Pletcher MT (2008). Genetic regulation of behavioral and neuronal responses to fluoxetine. Neuropsychopharmacology 33: 1312-1322.
86. Mineur YS, Belzung C, Crusio WE (2007). Functional implications of decreases in neurogenesis following chronic mild stress in mice. Neuroscience 150: 251-259.
87. Moller HJ (2002). Anxiety associated with comorbid depression. J Clin Psychiatry 63 (Suppl. 14): 22-26.
88. Monk CS, Telzer EH, Mogg K, Bradley BP, Mai X, Louro HM et al. (2008). Amygdala and ventrolateral prefrontal cortex activation to masked angry faces in children and adolescents with generalized anxiety disorder. Arch Gen Psychiatry 65: 568-576.
89. Monteggia LM, Barrot M, Powell CM, Berton O, Galanis V, Gemelli T et al. (2004). Essential role of brain-derived neurotrophic factor in adult hippocampal function. Proc Natl Acad Sci USA 101: 10827-10832.
90. Mortola JF, Liu JH, Gillin JC, Rasmussen DD, Yen SS (1987). Pulsatile rhythms of adrenocorticotropin (ACTH) and cortisol in women with endogenous depression: evidence for increased ACTH pulse frequency. J Clin Endocrinol Metab 65: 962-968.
91. Muck-Seler D, Jakovljevic M, Deanovic Z (1991). Effect of antidepressant treatment on platelet 5-HT content and relation to therapeutic outcome in unipolar depressive patients. J Affect Disord 23: 157-164.
92. Muck-Seler D, Jakovljevic M, Pivac N (1996). Platelet 5-HT concentrations and suicidal behaviour in recurrent major depression. J Affect Disord 39: 73-80.
93. Mulert C, Juckel G, Brunnmeier M, Karch S, Leicht G, Mergl R et al. (2007). Rostral anterior cingulate cortex activity in the theta band predicts response to antidepressive medication. Clin EEG Neurosci 38: 78-81.
94. Muller MB, Zimmermann S, Sillaber I, Hagemeyer TP, Deussing JM, Timpl P et al. (2003). Limbic corticotropin-releasing hormone receptor 1 mediates anxiety-related behavior and hormonal adaptation to stress. Nat Neurosci 6: 1100-1107.
95. Murray CJ, Lopez AD (1997). Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 349: 1498-1504.
96. Nemeroff CB (1996). The corticotropin-releasing factor (CRF) hypothesis of depression: new findings and new directions. Mol Psychiatry 1: 336-342.
97. Nemeroff CB, Widerlov E, Bissette G, Walleus H, Karlsson I, Eklund K et al. (1984). Elevated concentrations of CSF corticotropin-releasing factor-like immunoreactivity in depressed patients. Science 226: 1342-1344.
98. Nemeroff CB, Owens MJ, Bissette G, Andorn AC, Stanley M (1988). Reduced corticotropin releasing factor binding sites in the frontal cortex of suicide victims. Arch Gen Psychiatry 45: 577-579.
99. Nestler EJ, Carlezon WA Jr (2006). The mesolimbic dopamine reward circuit in depression. Biol Psychiatry 59: 1151-1159.
100. O'Leary OF, Bechtholt AJ, Crowley JJ, Hill TE, Page ME, Lucki I (2007). Depletion of serotonin and catecholamines block the acute behavioral response to different classes of antidepressant drugs in the mouse tail suspension test. Psychopharmacology (Berl) 192: 357-371.
101. O'Toole SM, Sekula LK, Rubin RT (1997). Pituitary-adrenal cortical axis measures as predictors of sustained remission in major depression. Biol Psychiatry 42: 85-89.
102. Palucha A, Klak K, Branski P, van der PH, Flor PJ, Pilc A (2007). Activation of the mGlu7 receptor elicits antidepressant-like effects in mice. Psychopharmacology (Berl) 194: 555-562.
103. Pariante CM (2003). Depression, stress and the adrenal axis. J Neuroendocrinol 15: 811-812.
104. Parker KJ, Schatzberg AF, Lyons DM (2003). Neuroendocrine aspects of hypercortisolism in major depression. Horm Behav 43: 60-66.
105. Pezawas L, Meyer-Lindenberg A, Drabant EM, Verchinski BA, Munoz KE, Kolachana BS et al. (2005). 5-HTTLPR polymorphism impacts human cingulate-amygdala interactions: a genetic susceptibility mechanism for depression. Nat Neurosci 8: 828-834.
106. Pittenger C, Duman RS (2008). Stress, depression, and neuroplasticity: a convergence of mechanisms. Neuropsychopharmacology 33: 88-109.
107. Pivac N, Muck-Seler D, Jakovljevic M (1997). Platelet 5-HT levels and hypothalamic-pituitary-adrenal axis activity in schizophrenic patients with positive and negative symptoms. Neuropsychobiology 36: 19-21.
108. Pizzagalli D, Pascual-Marqui RD, Nitschke JB, Oakes TR, Larson CL, Abercrombie HC et al. (2001). Anterior cingulate activity as a predictor of degree of treatment response in major depression: evidence from brain electrical tomography analysis. Am J Psychiatry 158: 405-415.
109. Raone A, Cassanelli A, Scheggi S, Rauggi R, Danielli B, De Montis MG (2007). Hypothalamus-pituitary-adrenal modifications consequent to chronic stress exposure in an experimental model of depression in rats. Neuroscience 146: 1734-1742.
110. Redrobe JP, Dumont Y, Fournier A, Baker GB, Quirion R (2005). Role of serotonin (5-HT) in the antidepressant-like properties of neuropeptide Y (NPY) in the mouse forced swim test. Peptides 26: 1394-1400.
111. Reif A, Fritzen S, Finger M, Strobel A, Lauer M, Schmitt A et al. (2006). Neural stem cell proliferation is decreased in schizophrenia, but not in depression. Mol Psychiatry 11: 514-522.
112. Ressler KJ, Mayberg HS (2007). Targeting abnormal neural circuits in mood and anxiety disorders: from the laboratory to the clinic. Nat Neurosci 10: 1116-1124.
113. Ribeiro SC, Tandon R, Grunhaus L, Greden JF (1993). The DST as a predictor of outcome in depression: a meta-analysis. Am J Psychiatry 150: 1618-1629.
114. Rocher C, Spedding M, Munoz C, Jay TM (2004). Acute stress-induced changes in hippocampal/prefrontal circuits in rats: effects of antidepressants. Cereb Cortex 14: 224-229.
115. Rogers MA, Kasai K, Koji M, Fukuda R, Iwanami A, Nakagome K et al. (2004). Executive and prefrontal dysfunction in unipolar depression: a review of neuropsychological and imaging evidence. Neurosci Res 50: 1-11.
116. Roy MA, Neale MC, Pedersen NL, Mathe AA, Kendler KS (1995). A twin study of generalized anxiety disorder and major depression. Psychol Med 25: 1037-1049.
117. Ruhe HG, Mason NS, Schene AH (2007). Mood is indirectly related to serotonin, norepinephrine and dopamine levels in humans: a metaanalysis of monoamine depletion studies. Mol Psychiatry 12: 331-359.
118. Rybakowski JK (2008). BDNF gene: functional Val66Met polymorphism in mood disorders and schizophrenia. Pharmacogenomics 9: 1589-1593.
119. Salome N, Stemmelin J, Cohen C, Griebel G (2006). Differential roles of amygdaloid nuclei in the anxiolytic- and antidepressant-like effects of the V1b receptor antagonist, SSR149415, in rats. Psychopharmacology (Berl) 187: 237-244.
120. Salvadore G, Cornwell BR, Colon-Rosario V, Coppola R, Grillon C, Zarate CA Jr et al. (2009). Increased anterior cingulate cortical activity in response to fearful faces: a neurophysiological biomarker that predicts rapid antidepressant response to ketamine. Biol Psychiatry 65: 289-295.
121. Sanacora G, Zarate CA, Krystal JH, Manji HK (2008). Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. Nat Rev Drug Discov 7: 426-437.
122. Santarelli L, Saxe M, Gross C, Surget A, Battaglia F, Dulawa S et al. (2003). Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science 301: 805-809.
123. Sargent PA, Kjaer KH, Bench CJ, Rabiner EA, Messa C, Meyer J et al. (2000). Brain serotonin1A receptor binding measured by positron emission tomography with [11C]WAY-100635: effects of depression and antidepressant treatment. Arch Gen Psychiatry 57: 174-180.
124. Saxena S, Brody AL, Ho ML, Zohrabi N, Maidment KM, Baxter LR Jr (2003). Differential brain metabolic predictors of response to paroxetine in obsessive-compulsive disorder versus major depression. Am J Psychiatry 160: 522-532.
125. Schinka JA, Busch RM, Robichaux-Keene N (2004). A meta-analysis of the association between the serotonin transporter gene polymorphism (5-HTTLPR) and trait anxiety. Mol Psychiatry 9: 197-202.
126. Schloesser RJ, Manji HK, Martinowich K (2009). Suppression of adult neurogenesis leads to an increased hypothalamo-pituitary-adrenal axis response. Neuroreport 20: 553-557.
127. Schweinhardt P, Kalk N, Wartolowska K, Chessell I, Wordsworth P, Tracey I (2008). Investigation into the neural correlates of emotional augmentation of clinical pain. Neuroimage 40: 759-766.
128. Sen S, Villafuerte S, Nesse R, Stoltenberg SF, Hopcian J, Gleiberman L et al. (2004). Serotonin transporter and GABAA alpha 6 receptor variants are associated with neuroticism. Biol Psychiatry 55: 244-249.
129. Shakesby AC, Anwyl R, Rowan MJ (2002). Overcoming the effects of stress on synaptic plasticity in the intact hippocampus: rapid actions of serotonergic and antidepressant agents. J Neurosci 22: 3638-3644.
130. Spedding M, Neau I, Harsing L (2003). Brain plasticity and pathology in psychiatric disease: sites of action for potential therapy. Curr Opin Pharmacol 3: 33-40.
131. Stemmelin J, Lukovic L, Salome N, Griebel G (2005). Evidence that the lateral septum is involved in the antidepressant-like effects of the vasopressin V1b receptor antagonist, SSR149415. Neuropsychopharmacology 30: 35-42.
132. Surget A, Saxe M, Leman S, Ibarguen-Vargas Y, Chalon S, Griebel G et al. (2008). Drug-dependent requirement of hippocampal neurogenesis in a model of depression and of antidepressant reversal. Biol Psychiatry 64: 293-301.
133. Szymanska M, Budziszewska B, Jaworska-Feil L, Basta-Kaim A, Kubera M, Leskiewicz M et al. (2009). The effect of antidepressant drugs on the HPA axis activity, glucocorticoid receptor level and FKBP51 concentration in prenatally stressed rats. Psychoneuroendocrinology 34: 822-832.
134. Tsankova NM, Berton O, Renthal W, Kumar A, Neve RL, Nestler EJ (2006). Sustained hippocampal chromatin regulation in a mouse model of depression and antidepressant action. Nat Neurosci 9: 519-525.
135. Ulrich-Lai YM, Herman JP (2009). Neural regulation of endocrine and autonomic stress responses. Nat Rev Neurosci 10: 397-409.
136. Utge S, Soronen P, Partonen T, Loukola A, Kronholm E, Pirkola S et al. (2009). A population-based association study of candidate genes for depression and sleep disturbance. Am J Med Genet B Neuropsychiatr Genet (in press).
137. Veen G, Derijk RH, Giltay EJ, van VI, van PJ, Zitman FG (2009a). The influence of psychiatric comorbidity on the dexamethasone/CRH test in major depression. Eur Neuropsychopharmacol 19: 409-415.
138. Veen G, Giltay EJ, Derijk RH, van VI, van PJ, Zitman FG (2009b). Salivary cortisol, serum lipids, and adiposity in patients with depressive and anxiety disorders. Metabolism 58: 821-827.
139. Vreeburg SA, Hoogendijk WJ, van PJ, Derijk RH, Verhagen JC, Van DR et al. (2009). Major depressive disorder and hypothalamic-pituitaryadrenal axis activity: results from a large cohort study. Arch Gen Psychiatry 66: 617-626.
140. Watson S, Gallagher P, Del-Estal D, Hearn A, Ferrier IN, Young AH (2002). Hypothalamic-pituitary-adrenal axis function in patients with chronic depression. Psychol Med 32: 1021-1028.
141. Whalen PJ, Johnstone T, Somerville LH, Nitschke JB, Polis S, Alexander AL et al. (2008). A functional magnetic resonance imaging predictor of treatment response to venlafaxine in generalized anxiety disorder. Biol Psychiatry 63: 858-863.
142. Wojnar M, Brower KJ, Strobbe S, Ilgen M, Matsumoto H, Nowosad I et al. (2009). Association between Val66Met brain-derived neurotrophic factor (BDNF) gene polymorphism and post-treatment relapse in alcohol dependence. Alcohol Clin Exp Res 33: 693-702.
143. Wray NR, James MR, Gordon SD, Dumenil T, Ryan L, Coventry WL et al. (2009). Accurate, large-scale genotyping of 5HTTLPR and flanking single nucleotide polymorphisms in an association study of depression, anxiety and personality measures. Biol Psychiatry 66: 468-476.
144. Wu J, Buchsbaum MS, Gillin JC, Tang C, Cadwell S, Wiegand M et al. (1999). Prediction of antidepressant effects of sleep deprivation by metabolic rates in the ventral anterior cingulate and medial prefrontal cortex. Am J Psychiatry 156: 1149-1158.
145. Yalcin I, Belzung C, Surget A (2008). Mouse strain differences in the unpredictable chronic mild stress: a four-antidepressant survey. Behav Brain Res 193: 140-143.
146. Yoshimizu T, Chaki S (2004). Increased cell proliferation in the adult mouse hippocampus following chronic administration of group II metabotropic glutamate receptor antagonist, MGS0039. Biochem Biophys Res Commun 315: 493-496.
147. Young EA, Altemus M, Lopez JF, Kocsis JH, Schatzberg AF, DeBattista C et al. (2004). HPA axis activation in major depression and response to fluoxetine: a pilot study. Psychoneuroendocrinology 29: 1198-1204.
148. Zarate CA Jr, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA et al. (2006). A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 63: 856-864.
149. Zhao C, Deng W, Gage FH (2008). Mechanisms and functional implications of adult neurogenesis. Cell 132: 645-660.
150. Zobel AW, Yassouridis A, Frieboes RM, Holsboer F (1999). Prediction of medium-term outcome by cortisol response to the combined dexamethasone-CRH test in patients with remitted depression. Am J Psychiatry 156: 949-951.
151. Zobel AW, Nickel T, Sonntag A, Uhr M, Holsboer F, Ising M (2001). Cortisol response in the combined dexamethasone/CRH test as predictor of relapse in patients with remitted depression. a prospective study. J Psychiatr Res 35: 83-94.